News Roche delays Spark merger again amid reviews in US and UK Richard Staines M&A, Roche, Spark 0 Comment Roche’s $4.3 billion takeover of US gene therapy specialist Spark Therapeutics has been pushed back again because regulators Share X Roche delays Spark merger again amid reviews in US and UK https://pharmaphorum.com/news/roche-delays-spark-merger-again-amid-reviews-in-us-and-uk/
News Roche to buy gene therapy firm Spark for $4.8 billion Richard Staines M&A, Rare diseases, Roche, Spark 0 Comment Roche is to buy gene therapy firm Spark Therapeutics for $4.8 billion, adding an already-approved treatment for inherited Share X Roche to buy gene therapy firm Spark for $4.8 billion https://pharmaphorum.com/news/roche-to-buy-spark-therapeutics/
Market Access/ News/ News Novartis/Spark’s sight gene therapy approved in EU Richard Staines market access, Novartis, ophthalmology, Rare diseases, Spark 0 Comment Spark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there Share X Novartis/Spark’s sight gene therapy approved in EU https://pharmaphorum.com/news/novartis-sparks-sight-gene-therapy-approved-in-eu/
